Beyond the Prescription Count: MASLD, Polypharmacy, and Moving to More Precise Deprescribing - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Rethinking Medication Burden in MASLD: Toward More Targeted Deprescribing

  • By

  • Daniella Lee

  • Alexander Chaitoff

  • November 16, 2026

Share

Clinical Scorecard: Rethinking Medication Burden in MASLD: Toward More Targeted Deprescribing

At a Glance

CategoryDetail
ConditionMetabolic dysfunction-associated steatotic liver disease (MASLD), defined here as hepatic steatosis greater than 5% on imaging or biopsy with at least one cardiometabolic risk factor.
Key MechanismsMASLD commonly coexists with cardiometabolic diseases requiring medication management; the article discusses potential medication-related harms and the challenge of distinguishing appropriate treatment from hazardous prescribing.
Target PopulationCommunity-dwelling adults aged 65 years and older, with particular attention to adults aged 75 years and older with MASLD.
Care SettingCommunity-dwelling older adults represented in a nationally representative NHANES analysis; the article also discusses individualized deprescribing research and shared decision-making.

Key Highlights

  • In NHANES 2017–2020, polypharmacy increased with age and was comparable between participants with and without MASLD across most age categories.
  • Among adults aged 75 years and older, polypharmacy prevalence was 60.3% with MASLD versus 42.7% without MASLD (p < 0.01).
  • Participants with MASLD had more cardiometabolic conditions, while cardiometabolic medication use was equivalent across most age categories.
  • In the oldest age group, MASLD was associated with more antihypertensive and antidiabetic prescriptions; sedating medication use and hyperpolypharmacy did not differ between groups.
  • The article states that evidence remains limited on whether reducing medication counts improves clinical outcomes or patient satisfaction.

Guideline-Based Recommendations

Diagnosis

  • The study identified MASLD using image-guided assessment of hepatic steatosis alongside exam- or medication-derived evidence of cardiometabolic risk.

Management

  • The article says clinicians need to involve patients in shared decision-making about treatment risks and benefits.
  • The authors suggest that deprescribing research could focus on people with conditions that may heighten frailty risk or alter medication metabolism, and on high-risk individuals unlikely to benefit from continued medication.

Monitoring & Follow-up

  • The authors call for further epidemiologic research assessing clinical outcomes across different levels of medication use in people with MASLD.
  • The authors call for research to establish whether structured, individualized deprescribing interventions affect outcomes in this population.

Risks

  • The source notes that older adults are susceptible to harms associated with polypharmacy, including mortality.
  • Higher medication use may represent appropriate treatment or potentially hazardous prescribing; the study does not resolve which applies to most patients with MASLD.

Patient & Prescribing Data

Community-dwelling adults aged 65 years and older in NHANES 2017–2020; the reported age-specific difference was among participants aged 75 years and older.

Among those aged 75 years and older, polypharmacy prevalence was 60.3% with MASLD and 42.7% without MASLD. In this group, participants with MASLD had more antihypertensive and antidiabetic prescriptions, but sedating medication use and hyperpolypharmacy did not differ.

Clinical Best Practices

  • The article says clinicians need to involve patients in shared decision-making about treatment risks and benefits.
  • The study does not establish whether higher medication counts indicate undertreatment, overtreatment, or appropriate treatment.
  • The authors call for research on individualized deprescribing approaches; evidence remains limited on whether reducing medication counts improves clinical outcomes or patient satisfaction.

Related Resources & Content

Original Source(s)

Related Content